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Abstract: Friedreich ataxia is a neurodegenerative disease with an autosomal recessive inheritance.
In most patients, the disease is caused by the presence of trinucleotide GAA expansions in the first
intron of the frataxin gene. These expansions cause the decreased expression of this mitochondrial
protein. Many evidences indicate that frataxin deficiency causes the deregulation of cellular iron
homeostasis. In this review, we will discuss several hypotheses proposed for frataxin function,
their caveats, and how they could provide an explanation for the deregulation of iron homeostasis
found in frataxin-deficient cells. We will also focus on the potential mechanisms causing cellular
dysfunction in Friedreich Ataxia and on the potential use of the iron chelator deferiprone as a
therapeutic agent for this disease.
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1. The Disease
Friedreich’s Ataxia (FRDA) is a neurodegenerative disease described at the end of the 19th century
by the German physician Nikolaus Friedreich from whom acquired the name. Friedreich observed
in a group of patients that during the puberty a characteristic symptomatology began to manifest,
specifically: ataxia, dysarthria, loss of sensitivity, muscle weakness, scoliosis, pes cavus, and heart
symptoms. Later, a greater incidence of diabetes mellitus in patients than in the rest of the population
was also reported [1]. It is considered a rare disease that follows a pattern of autosomal recessive
inheritance. The frequency of carriers oscillates, depending on the area, between 1:50 and 1:100,
while those affected by the disease are approximately 1:50,000, which makes this disease the most
common form of hereditary ataxia [2].
The mutation responsible for the disease is an expansion of GAA trinucleotides in the first intron of
the FXNor X25 gene (located in chromosome 9), which codes for the mitochondrial protein frataxin [3].
This expansion of triplets, which in patients can reach up to more than 1000 copies, results in a marked
decrease in protein frataxin levels (below 5%–30% of normal levels) [4]. The number of GAA expansions
has an inversely proportional relation to the age at which the first symptoms of the disease begin to
manifest and it also determines their severity [5–7]. Besides GAA expansions, epigenetic modifications
might also contribute to the variability in the onset and disease progression. Sarsero and collaborators
reported differences in DNA methylation patterns between patients upstream and downstream the
GAA expansion. Such differences caused variations in frataxin gene expression [8]. Finally, a small
percentage of patients, around 4%, are compound heterozygous for a GAA expansion and a frataxin
(FXN) point mutation or deletion [9].
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2. Frataxin, an Ancestral Conserved Protein
Frataxin is a highly conserved protein throughout evolution and homologues can be found in
most species. Its structure is formed by two helix alpha joined by a series of antiparallel beta sheets
and is highly conserved (Figure 1). Despite the high degree of conservation in the three-dimensional
structure, the stability of this protein varies significantly between species. One of the factors that are
responsible for the differences in the stability of the protein is the C-terminal endpoint. While in Yfh1
(the yeast’s homologue), this region is virtually nonexistent, in the human protein this fragment is
found inserted between the two alpha helixes. This protects the hydrophobic nucleus of the protein
and increases its stability [10].
1 
 
Figure 1. Structures of human frataxin (hFxn, pdb code 3s4m) and Yeast Frataxin Homologue 1
(Yfh1, pdb code 2fql). Top, ribbons representations showing the conserved alpha-beta-alpha structure.
Structures are colored according to sequence, from dark blue (N-terminal) to red (C-terminal). In human
frataxin the C-terminal region folds over the hydrophobic cavity formed between both alpha helices.
Below, coulumbic surface coloring of the same structures. The red color indicates the presence of a
marked acidic ridge, which may be involved in iron binding. Molecular graphics and analyses were
performed with the UCSF Chimera package [11].
Frataxin is a mitochondrial protein, and as such, it has a signal peptide at its N-terminal end.
It was soon identified, both for Yfh1 and for mouse frataxin, that Mitochondrial Processing Peptidase
interacted with frataxin and was responsible for its processing [12,13]. This processing involves
two sequential cleavages, which first produce an intermediate form of frataxin and subsequently
the mature form. For human frataxin, the cleavage positions described are between amino acids
41–42 (intermediate form) and between amino acids 80–81 (mature form), although other less abundant
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forms that correspond to alternative cleavage sites (for instance, positions 55–56) have also been
identified [14,15]. In these works, it was shown that the mature form of frataxin corresponds to
FXN81–210. This form is fully active and capable of improving the survival and phenotypes of frataxin
deficient cells. Despite the demonstration that the FXN81–210 form is the dominant form and that it is
active, there is some debate over the role that could be developed by the intermediate forms, as these
forms can also be detected in certain tissues (although at low levels) [16]. It was shown that processing
of the intermediate form was slower than that of the precursor form, which suggested that this could
be a mechanism for controlling the levels of the different frataxin forms [17]. More recently, it has been
suggested that the different forms of frataxin might play different roles. This point will be discussed in
the next section. In addition to post-translational processing, alternative splicing mechanisms have
also been observed that may generate different isoforms of frataxin. Work by Xia and collaborators
suggested that these alternative forms could be tissue-specific and could have different functions and
locations [18]. However, there are not additional evidences about the nature and relevance of these
alternative forms.
3. Frataxin Function
Although very early after the discovery of frataxin as the gene that was responsible for Friedreich’s
Ataxia, it was established that iron homeostasis was altered by frataxin deficiency, the specific function
of this protein remains controversial. Over the years, different functions have been proposed for
frataxin, most of them related to iron metabolism and the control of oxidative stress in mitochondria.
3.1. Frataxin, an Iron Binding and Storage Protein
It has been proposed that frataxin could work like a metalochaperone and iron storage protein.
In several studies with purified protein, it has been observed that frataxin has the ability to interact
with metal ions, but the coordination environment of these metal binding sites has not been properly
defined. There is also uncertainty on the number of metal ions that are bound per frataxin monomer.
It has been described that frataxin can bind divalent metal ions using a group of exposed acidic
residues. These amino acids are located in a specific area of the protein forming an acidic ridge,
quite conserved, different from the canonical iron binding motifs where cysteine and/or histidine
amino acids are usually found. This acidic zone results in a weak and non-specific electrostatic bonding
of iron, which also allows the coordination of other divalent metals [19]. The estimated Kd for Fe2+
and Fe3+ of this region was calculated on the micromolar range [20]. Gentry and collaborators reported
the potential presence of a high affinity iron binding site. They showed that three metal ions could
be bound by each frataxin monomer, and that His86 was required for one of these binding sites.
This residue is located in the disordered N-terminal tail and had not been previously reported to be
involved in metal coordination. They calculated that this site would have an affinity for Fe2+ higher
than the iron chelator ferrozine, while the remaining two sites would have lower affinities [21]. His86 is
not included in most of the frataxin structures that are found in the protein data bank nor is conserved
in yeast and bacterial homologues. More recently, while using NMR to investigate iron binding, it was
also proposed that frataxin tightly binds a single Fe2+ but not Fe3+ [22].
Isaya and collaborators noticed that iron binding to yeast and bacterial frataxin promoted its
oligomerization to complexes of high molecular weight (850–1100 kDa) [23–25]. These oligomeric
forms resembled those that were formed by ferritin, the main protein responsible for iron storage
in eukaryotes. Indeed, oligomeric frataxin was shown to use a ferrooxidation reaction to build a
ferrihydrite mineral core inside the particles. Therefore it was proposed that frataxin could act as
a mitochondrial ferritin. Although this function would be redundant in higher eukaryotes due to
the presence of a mitochondrial ferritin, this hypothesis acquired some strength when subsequent
studies demonstrated that the expression of mitochondrial ferritin in frataxin deficient yeast was able
to partially recover some of the observed phenotypes. Specifically, the heterologous expression of
mitochondrial ferritin partially prevented the accumulation of iron, the cells were more resistant to
Pharmaceuticals 2018, 11, 89 4 of 15
oxidizing agents and they partially recovered the activities of enzymes with iron-sulfur centers (which
is a common described consequence of frataxin deficiency) [26]. Regarding human frataxin, it has been
claimed that the mature form (FXN81–210) does not form aggregates [27] and that only the intermediate
forms FXN42–210 and FXN56–210 would be assembled into larger structures. Based on this observation,
it has been suggested that different frataxin proteoforms would perform different functions. The mature
form would be monomeric and involved in iron binding and delivery to biochemical pathways
requiring this metal, while FXN56–210 and FXN42–210 would be able to oligomerize and store iron.
A caveat to these hypotheses is that the long frataxin isoforms are not observed in most tissues by
western blot. Mass spectrometry data also suggests that these long frataxin isoforms may be present at
very low concentrations: data collected in the PeptideAtlas repository indicates that the theoretically
likely frataxin peptides between positions 42 and 81 have never been observed, while those from the
FXN81–210 have been observed at least 400 times. (PeptideAtlas is a publicly accessible compendium of
peptides identified in mass spectrometry proteomics experiments) [28]. Recently, it has been shown
that FXN81–210 can also undergo oligomerization under certain conditions, although the stability of
these oligomers would be lower than that of bacterial frataxin [29].
Nevertheless, there are other caveats on the ferritin-like hypothesis. It has been argued that
physiological conditions of calcium and magnesium stabilize the monomeric frataxin form and
consequently frataxin would not oligomerize in vivo [27]. It has also been shown that mitochondrial
iron in yeast strains expressing different Yfh1 concentrations, presented nearly identical chemical and
biochemical characteristics [30]. Another point to take into account is which could be the contribution
of frataxin to mitochondrial iron storage or trafficking from a quantitative point of view. Most iron
that is present in mitochondria is found at the active sites of proteins. Despite that, non-proteinaceous
labile metal iron pools have also been detected within cells. These pools are thought to be involved
in cellular trafficking, regulation, signaling, and/or storage of metal ions. Due to their lability (and
their presence at low concentrations), their structure and functions are not completely understood.
For instance, mitochondria contain 0.7–2 mM Fe, but the proportion of labile iron is not completely
known, with estimates ranging from 1 to 100 µM [31,32]. These differences in the estimates may be due
to real differences between the models or experimental conditions used, but also on the methodological
approaches used to analyze this elusive iron pool. Also, the nature of these nonproteinaceous metal
complexes is not known. Based on the abundance of GSH within the mitochondria it has been
hypothesized that could be an FeII (GSH) adduct. Citrate, which is also present in the mitochondrial
matrix at high concentrations, has also been considered as a potential ligand for non-proteinaceous
iron complexes (reviewed in [32]). In yeast, by using Mössbauer spectroscopy, it has been shown
that the proportion and nature of these labile iron pools may vary depending on the metabolic state
of the cell. Respiring mitochondria where estimated to contain ∼15 µM labile non-heme high spin
Fe2+, while this pool in fermenting mitochondria increased to ∼150 µM. The concentration of yeast
frataxin in mitochondria has been estimated to be three orders of magnitude lower, around 35 nM [33].
Therefore, as monomeric frataxin has been claimed to bind three iron atoms, it cannot contribute
significantly to store iron in a non-reactive easy deliverable form. However, it could play a role in iron
trafficking as a temporary carrier or catalyzing its speciation between different forms. For instance,
it could bind Fe2+ and promote its controlled oxidation to Fe3+, which would be then stored in the form
of Fe3+-phosphate nanoparticles. Regarding oligomeric frataxin, the mineralization process would
allow for this protein to bind much more iron atoms per subunit. The yeast 48 subunit oligomer can
store ∼50–75 iron atoms per subunit in 1–2 nm cores [34]. This raises the iron potentially bound by
frataxin up to the µM range, but still this amount may not be a significant contribution to the whole
mitochondrial iron pool. In comparison, around 35% of mitochondrial iron in fermenting mitochondria
may be stored in the form of Fe3+ nanoparticles [33]. That said, the contribution of mitochondrial
ferritin to iron storage in mitochondria is also intriguing, as the concentration of this protein according
to the PaxDb database is much lower than that of frataxin (PaxDB is a database that contains protein
abundance information across organisms and tissues) [35].
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3.2. Frataxin in the Biosynthesis of Iron Containing Proteins
It has also been proposed that frataxin could participate in the biosynthesis of both heme groups
and of iron-sulfur centers. This hypothesis has several fundamentals: (a) frataxin deficiency leads to a
loss in proteins which contain iron-sulfur centers or heme groups; (b) frataxin has the ability to bind
iron atoms; and, (c) several studies have shown the ability of frataxin to interact with proteins that
areinvolved in heme or iron-sulfur biosynthesis.
3.2.1. Biosynthesis of Heme Groups
The incorporation of the iron atom into protoporphyrin IX is the last step in the biosynthesis of
heme groups. This step is catalyzed by ferrochelatase, but it is not known how iron is provided to
this enzyme. In in vitro studies, it was shown that there was a physical interaction between frataxin
and ferrochelatase with a 1 to 2 stoichiometry, which seems logical, since ferrochelatase functions
as a dimer. In addition, this interaction resulted in the formation of heme groups [36]. A study in
which NMR spectroscopy was used to analyze the binding between both of the proteins suggested
that ferrochelatase interacted with frataxin in a manner that included its iron-binding interface [37].
More recently, Söderberg and collaborators presented a model of the interaction of trimeric Yfh1 (yeast
frataxin) and ferrochelatase in which one of the subunits of the Yfh1 trimer interacted with one subunit
of the ferrochelatase dimer, whereas another trimer subunit was positioned for iron delivery [38].
These results support the hypothesis of frataxin acting as an iron donor in the biosynthesis of heme
groups. However, heme deficiency is not always observed in frataxin-deficient cells and anemia has
not been shown to be a symptom of FRDA. Indeed, no alterations where observed in heme synthesis
in erythroid progenitor stem cells that were obtained from FRDA patients [39]. Moreover, experiments
using either conditional frataxin-deficient T-Rex-293 cells or yeasts have shown that heme deficiency
is a late consequence of frataxin deficiency [40,41]. These observations suggest that heme deficiency
may be an epiphenomenon observed in certain frataxin-deficient cells which could be caused by poor
iron availability or by metabolic remodeling. In this regard, we have shown in frataxin-deficient yeast
that heme deficiency could be caused by the induction of Cth2, a protein induced in response to iron
limitation, which promotes the degradation of mRNAs from iron-containing proteins [42].
3.2.2. Biosynthesis of Iron-Sulfur Centers
In addition to interacting with ferrochelatase, frataxin also interacts with the proteins that form
the central biosynthesis machinery of iron-sulfur centers: IscU (Isu1 in yeast), Nfs1, and Isd11 [43,44].
Several authors have shown that this interaction facilitates the formation of an iron-sulfur center
into IscU, the scaffold protein where these cofactors are first assembled. It was initially suggested
that frataxin would act as an iron donor in the biosynthesis of these centers [45]. More recently,
it has been suggested that frataxin would participate in the biosynthesis of iron-sulfur centers as an
allosteric regulator and not as an iron donor. In works that were carried out in vitro with the CyaY
protein (bacterial homologue of frataxin), it was shown that this protein had an inhibitory effect on
the production of iron-sulfur centers. As this effect was increased in response to iron concentration,
the authors suggested that frataxin could adapt the production of iron-sulfur to the number of final
acceptor proteins [46]. Surprisingly, studies with human proteins demonstrated that eukaryotic
frataxins would have a contrary effect. In this case, they stimulated the production of iron-sulfur
centers by favoring the desulfurase activity of Nfs1 [47–49].
Today, despite the intense debate that is generated around the function or functions of frataxin,
this non-essential activity in the metabolism of iron as an allosteric regulator of the biosynthesis
of iron-sulfur centers has strong support from in vitro biochemical data and is the most accepted
hypothesis. A detailed explanation of this complex biochemical process can be found in recent
reviews [50,51]. However, this hypothesis also presents caveats when exposed to in vivo biological
data. Remarkably, iron-sulfur cluster deficiency is not observed in several models of frataxin deficiency,
Pharmaceuticals 2018, 11, 89 6 of 15
such as flies [52], patient fibroblasts [53], or rat cardiac myocytes [54]. Moreover, detailed analysis
of the cellular events that are caused by frataxin deficiency in yeast, have shown that iron-sulfur
deficiency is an epiphenomenon that is caused by a metabolic remodeling program activated in
response to disrupted iron homeostasis [41,55]. These observations question the role of frataxin in
iron-sulfur biogenesis or at least suggest the possibility of additional functions for frataxin beyond
iron-sulfur biogenesis. From these observations, it also becomes obvious that frataxin is not essential
for iron-sulfur biogenesis.
3.3. Control of Oxidative Stress and the Generation of Ros
One of the phenotypes most consistently observed in frataxin-deficient cells is sensitivity to
oxidizing agents [56,57]. Some authors have linked such sensitivity to oxidative stress to impaired
biosynthesis of iron-sulfur centers. This hypothesis suggests that a vicious cycle would be created in
which the deficient formation of iron-sulfur clusters would increase mitochondrial free iron that would
increase the production of reactive oxygen species (ROS) through Fenton reaction. Then, ROS would
further damage iron-sulfur clusters and promote the formation of more free iron. In fact, increased
presence of labile iron has been reported in frataxin deficient yeast [58], T-Rex-293 cells [40] and in
a mouse model of hepatic FXN deficiency [59]. However, no differences where observed between
the mitochondrial iron pools from human lymphoblasts and fibroblasts that were obtained from
either controls or FRDA patients [31]. Nevertheless, some observations suggest that oxidative stress
could be the cause (and not the consequence) of iron-sulfur deficiency. For instance, in fibroblasts or
lymphocytes from patients [53], or in frataxin-deficient cardiac myocytes [54], oxidative stress could be
observed while the activities of iron-sulfur proteins remained unaltered. Moreover, there are evidences
that iron-sulfur deficiency can be modulated by oxygen concentration or antioxidant treatment. In this
regard, frataxin is not required for iron-sulfur biogenesis in yeasts grown at low oxygen tensions [60,61].
In some fly models, iron-sulfur deficiency is only observed under hyperoxic conditions [52], while in
other models it can be prevented by antioxidants [62].
Which could be the origin of oxidative stress? Since frataxin has the ability to bind iron, a redox
active metal, and oxidize it to Fe3+, it has been proposed that frataxin could prevent oxidative stress by
limiting the presence of free Fe2+ through its binding and the subsequent controlled oxidation to Fe3+.
This reaction would prevent the formation of reactive oxygen species through the reaction of Fe2+ with
oxygen [63,64]. Therefore, the vicious cycle would have its origin in free iron than would then generate
oxidative stress that would damage iron-sulfur clusters and generate more free iron. Another potential
source of reactive oxygen species in frataxin-deficient cells could be the OXPHOS system. In this
regard, an interaction was described between frataxin and mitochondrial electron transport chain
proteins [65]. Also, decreased activity of the mitochondrial electron transport chain has been observed
in several biological models of frataxin deficiency [53,66,67]. Any alteration in the OXPHOS system
that was caused by frataxin deficiency could increase electron leakage and thus generate ROS [68].
Rustin and collaborators observed that frataxin-deficient cells could not properly activate the
NRF2 signaling pathway in response to oxidative damage and in consequence they had a deficient
response to oxidative insults and hypersensitivity to oxidative stress. They hypothesized that
this impairment was related to actin remodeling [69]. This phenomenon has also been described
in frataxin-deficient motor neurons [70], and in the frataxin-deficient YG8R mouse model where
transcriptomic analysis showed a downregulation of NRF2-dependent antioxidant enzymes [71].
4. Evidences of Iron Accumulation and Its Relation to Pathophysiology in FRDA
Iron accumulation in a frataxin deficient cell model was first described in yeast yfh1 mutants [72].
This early observation has been subsequently confirmed by several other researchers. Using Mössbauer
spectroscopic analysis, Dancis and collaborators showed that in Dyfh1 mitochondria iron was present
as amorphous nano-particles of ferric phosphate [73]. Iron accumulation is caused by increased iron
uptake due to activation of the iron sensor Aft1 [58], but the mechanisms leading to such activation are
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not completely understood. It has been assumed that it would be caused by iron-sulfur cluster loss,
as Aft1 is known to be regulated by the presence of these cofactors. However, previous research from
our group using conditional Yfh1 mutants provided two observations that challenged this hypothesis:
(i) activation of Aft1 was observed earlier than iron-sulfur loss [41]; and, (ii) loss of iron-sulfur
containing proteins in Yfh1 deficient yeasts was not observed in cth2 cells. Therefore iron-sulfur loss
was an epiphenomenon mainly caused by Cth2, which is an Aft1 target that binds to mRNAs from
iron-containing proteins and promotes its degradation [42]. Moreover, we have also observed that nitric
oxide can prevent Aft1 activation in Yfh1-deficient cells, but not in cells that are deficient in iron-sulfur
biogenesis [74]. This observation also indicates that in Yfh1 deficient yeast Aft1 may be activated by a
mechanism different than iron-sulfur cluster deficiency. Besides yeast, iron deposits or accumulation
have also been clearly observed in frataxin deficient flies [75,76] and in cardiac muscles from frataxin
deficient mice [77] and FRDA patients [78]. Iron in the heart from cardiac KO conditional mouse (the
MCK mutant) was found in mitochondrial aggregates 100–400 nm in diameter, markedly different from
those observed for mammalian ferritin. Energy-dispersive X-ray analysis showed that, in addition
to iron, phosphorus and sulfur were present in these aggregates. Mössbauer spectra also confirmed
that these aggregates where different than mammalian ferritin. The absorption profile observed was
consistent with paramagnetic high-spin Fe(III) [79]. These observations are consistent with those that
were obtained in frataxin-deficient yeast, and suggest that iron could be in the form of ferric-phosphate
nanoparticles in both models. In other tissues or mammalian cell types, iron accumulation is not
consistently observed. For instance, in fibroblasts or lymphoblasts from patients, there are no evidences
of iron accumulation [31], while some authors have observed it in the nervous system [80]. Changes
in the iron-responsive proteins, ferritin, divalent metal transporter 1 (DMT1), transferrin receptor
1 (TfR1), and ferroportin have been reported in the dentate nucleus of affected individuals [81].
Similar to yeast, iron deregulation in mammals might be caused by Iron-responding protein 1 (IRP1)
activation [82,83], but the mechanisms causing this activation are not completely understood. It could
be caused by deficiencies in iron supply to mitochondrial iron-dependent pathways that would activate
the mechanisms of response to iron deficiency [59]. Frataxin has also been shown to interact with
IRP1 and modulate the switch between its aconitase and RNA-binding forms. This function would be
carried on by a cytosolic form of frataxin [84]. However, some authors are skeptical about the existence
of an extra mitochondrial form of frataxin, and therefore question the physiological relevance of the
observed interaction between IRP1 and frataxin.
As indicated above, many evidences support that frataxin deficiency causes a dysregulation in
iron homeostasis, and it has also been shown in several models that the modulation of iron homeostasis
ameliorates several phenotypes caused by frataxin deficiency [74,85]. However, the contribution of
iron accumulation to the pathophysiology of FRDA has not been clearly determined. In this regard,
several hypotheses have been formulated. It has been proposed that iron accumulation would be toxic
and could be contributing to the formation of reactive oxygen species through the Fenton reaction.
Iron overload could be also inducing the synthesis of sphingolipids, which, through the Pdk1/Mef2
pathway, would trigger neurodegeneration [76,80]. Iron toxicity could be also related to the formation
of iron-phosphate aggregates that would compromise phosphate availability [86]. Nevertheless,
it has also been suggested that iron accumulation would not be toxic per se, and that pathological
consequences of frataxin deficiency would be mostly related to deficient iron supply to iron-dependent
proteins. In this regard, it has been shown that IRP1 activation has a protective effect in a mouse model
of hepatic FXN deficiency, as it contributes to sustain mitochondrial iron needs and mitochondrial
function in these mice [59]. It has also been observed that dietary iron supplementation limits cardiac
hypertrophy in MCK mutant mice [79].
These contradictory observations suggest that the pathological mechanisms could be more
complex and specific for different models and tissues. For instance, in yeast, we have observed that
activation of Aft1 causes the overexpression of Cth2, an mRNA binding protein that downregulates
the expression of most iron-binding proteins that are required for aerobic growth. Thus, the activation
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of such pathway has a strong contribution to the alterations observed in yeast [42]. Beyond yeast,
there are several evidences that frataxin deficiency may be causing perturbations in signaling pathways
that could contribute to pathology. For instance, as mentioned before, neurodegeneration has been
linked to the activation of the Pdk1/Mef2 pathway [76,80]. Cardiac hypertrophy could be related to the
activation of the NFAT/calcineurin pathway, which has been observed in rat frataxin deficient cardiac
myocytes [87]. Therefore, pathophysiology could be related to the pathways activated in different cells
and tissues in response to the perturbations caused by frataxin deficiency.
Besides iron, some authors have reported deregulation of the homeostasis of other metals as a
consequence of frataxin deficiency. In frataxin deficient yeast, we observed a decrease in manganese
content and limited copper availability [58,88]. Subsequent studies using a conditional frataxin mutant
indicated that manganese deficiency was caused by downregulation of Smf2, a Mn transporter that
was degraded in response to iron accumulation [41]. In frataxin deficient flies it was found that the
levels of zinc, copper, and manganese were increased, and that copper and zinc chelation improved the
impaired motor performance of these flies [89]. In Dorsal Root Ganglia from FRDA patients, zinc and
iron related proteins displayed major shifts in their cellular localization [90]. Alterations in calcium
homeostasis have also been reported in several models of FRDA [87,91]. These alterations are mostly
considered to be consequences of the deregulation of iron homeostasis, which may impact other metals.
Nevertheless, frataxin is known to have also the capacity to chelate metals that are different than
iron, such as manganese or copper [92]. The biological significance of these interactions has not been
explored yet.
5. Targeting Iron as a Therapeutic Approach in FRDA
There is currently no cure for FRDA but several therapeutic approaches are being investigated.
Some drugs have already entered clinical trials. Briefly, therapeutic approaches can be divided into
compounds that improve mitochondrial function and reduce oxidative stress, drugs that modulate the
altered metabolic pathways, and strategies to increase the expression or content of frataxin, either by
promoting its expression, by supplying it through gene therapy (reviewed in [93]) or by protein
replacement strategies [94].
Due to the alterations that were observed in iron homeostasis in different models and patients of
FRDA, the use of iron chelators as a treatment to eliminate the excess iron accumulating in mitochondria
was proposed many years ago. Deferoxamine was not considered to be a suitable iron chelator for
depleting the intracellular iron deposits found in FRDA, as it does not cross the blood brain barrier and
poorly penetrates biological membranes. It also has a high affinity for iron, which could compromise
iron availability. The proposed alternative was deferiprone, an orally administered, lipidsoluble iron
chelator that had been previously used to treat iron overload in polytransfused individuals with
hemoglobinopathies. This compound can easily cross the blood–brain barrier and cellular membranes
and therefore reach intracellular (or mitochondrial) iron deposits. In addition, since its affinity for iron
is lower than that of transferrin, it has been shown that it can redistribute iron from intracellular iron
deposits to this protein [95]. Indeed, the cellular properties that are affected by frataxin deficiency in
HEK-293 cells were corrected by deferiprone treatment [96].
Several clinical trials have been performed with deferiprone in FRDA patients. In summary,
these studies suggested that low doses of deferiprone would be beneficial on cardiac parameters.
Higher doses of the drug worsened the condition and could result in agranulocytosis (reviewed
in [97]). We can speculate that this dose dependent effect could be a consequence of different
pathological mechanisms that are exerted by frataxin deficiency. Some of them would be caused by
iron accumulation, while others would be caused by deficient iron availability. Therefore, low doses of
the chelator would partially prevent the toxic effects that are caused by iron accumulation, while higher
doses of deferiprone would compromise iron availability, and therefore worsen those pathological
conditions caused by inefficient iron availability. Nevertheless, it has been proposed that deferiprone
at low doses could be combined with other drugs. A pilot study with five FRDA patients suggested
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that combined therapy of deferiprone and idebenone (a Q10 analogue) was relatively safe and it could
provide some benefits on neurological function and heart hypertrophy [98].
6. Concluding Remarks
Many evidences indicate that the lack of frataxin leads to alterations in iron cellular homeostasis.
However, the precise mechanism(s) causing iron deregulation in frataxin-deficient cells are not
completely understood. Several hypotheses have been formulated, but although most of them are well
supported by in vitro data, all of them present caveats when exposed to biological data. In Figure 2,
we have summarized two potential mechanisms which in our opinion could explain iron accumulation
and oxidative stress: (1) the iron-sulfur hypothesis proposes that frataxin contributes to iron-sulfur
biogenesis and its deficiency activates cellular iron sensors that would promote iron uptake; and, (2) the
iron toxicity hypothesis assumes that frataxin would be involved in controlled iron ferrooxidation,
and its deficiency would lead to ROS generation and the increased formation of ferric-phosphate
nanoparticles. The iron-sulfur hypothesis is well supported by in vitro data, but its major caveat is the
absence of iron-sulfur deficiency in many models of frataxin deficiency. On the other hand, the iron
toxicity hypothesis does not provide a clear explanation for the activation of iron sensors.
 
2 
 
Figure 2. Potential contribution of frataxin to iron homeostasis and cellular consequences of its
deficiency. (A), physiological: frataxin (FXN) binds Fe2+ and contributes to its controlled oxidation to
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Fe3+ and/or to incorporate it into Fe-containing proteins. These Fe-containing proteins (notably FeS
proteins) keep the iron sensor inactive and genes involved in iron uptake are not expressed. Oxidized
iron (Fe3+) is stored in the form of ferric-phosphate nanoparticles. (B), frataxin-deficient: loss of frataxin
leads to decreased incorporation of iron into Fe-proteins and/or uncontrolled oxidation of Fe2+ by
O2. Such events lead to reactive oxygen species (ROS) generation, decreased phosphate availability,
and mitochondrial dysfunction. Iron sensors and other cell signaling pathways are activated and
regulate the expression of genes involved in iron uptake and/or other cell-specific pathways involved
on metabolic remodeling, hypertrophy or neurodegeneration.
Also, it is not clear the contribution of iron to FRDA pathology, which could be related either to
iron accumulation or to limited iron availability. Indeed, iron homeostasis deregulation could be an
epiphenomenon that is not linked to pathology. In fact, many evidences suggest that the mechanisms
causing cellular dysfunction could be tissue or model specific. They could also be related to the
signaling pathways activated in response to the alterations that are caused by frataxin deficiency.
This complexity may explain the limited effects of iron chelators on clinical trials, as these compounds
would only prevent certain pathological mechanisms in a limited number of tissues.
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